In the early hours of September 14, 2021, three men parked in a quiet car park in the southern English market town of ...

A good night's sleep often sets the stage for a positive day. But for the nearly quarter of American adults struggling with ...

The FDA granted breakthrough status to Serial CTRS, an AI tool that improves survival predictions in non–small cell lung ...

The rate of antiviral prescriptions was 67% lower in pregnant than in nonpregnant women, including those with one or more high-risk underlying conditions.

Incyte Corp on Monday forecast annual sales of its skin disorder treatment Opzelura below Wall Street estimates, sending the drugmaker's shares down as much as 9% in afternoon trade. The company is ...

Donald Trump's decision to cut vital aid has stunned health officials and charities working to fight HIV and AIDS. One told ...

As Washington combats overdoses from fentanyl and other drugs, addiction centers say a gap in funding for patients' room and ...

Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.

Rockville’s MaxCyte has made its first acquisition in its more than quarter-century of operation. It’s keeping its eyes out ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...